Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients

Schizophrenia Research

Volumn 108, Issue 1-3, 2009, Pages 122-126

  Bai, Ya Mei ^a,b   Chen, Jen Yeu ^c   Chen, Tzu Ting ^c   Lin, Chih Yuan ^c   Chou, Pesus ^d   Su, Tung Ping ^a,b   Lin, Chao Cheng ^e,f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d Institute of Clinical Medicine and Cardiovascular Research Institute   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Clozapine; Weight gain

Indexed keywords

CLOZAPINE; LITHIUM; VALPROIC ACID;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COMPARATIVE STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CLOZAPINE; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 60249087027     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.10.023     Document Type: Article

References (19)

1. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158 (2001) 518-526
2. Lamberti J.S., Bellnier T., and Schwarzkopf S.B. Weight gain among schizophrenic patients treated with clozapine. Am. J. Psychiatry 149 (1992) 689-690
3. Hummer M., Kemmler G., Kurz M., Kurzthaler I., Oberbauer H., and Fleischhacker W.W. Weight gain induced by clozapine. Eur. Neuropsychopharmacol 5 (1995) 437-440
4. Harris E., and Eth S. Weight gain during neuroleptic treatment. Int. J. Nurs. Stud. 18 (1981) 171-175
5. Umbricht D.S., Pollack S., and Kane J.M. Clozapine and weight gain. J. Clin. Psychiatry 55 Suppl B (1994) 157-160
6. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., and Goff D.C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry 157 (2000) 975-981
7. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 29 (2006) 303-319
8. Byerly M.J., Fisher R., Carmody T., and Rush A.J. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 66 (2005) 997-1001
9. Remington G., Kwon J., Collins A., Laporte D., Mann S., and Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr. Res. 90 (2007) 229-237
10. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
11. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., and Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J. Clin. Psychiatry 62 (2001) 231-238
12. Haddad P.M., and Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21 (2007) 911-936
13. Covell N.H., Weissman E.M., and Essock S.M. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr. Bull. 30 (2004) 229-240
14. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., and Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 (1997) 407-418
15. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., Breier A., and Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch. Gen. Psychiatry 57 (2000) 249-258
16. Gureje O., Miles W., Keks N., Grainger D., Lambert T., McGrath J., Tran P., Catts S., Fraser A., Hustig H., Andersen S., and Crawford A.M. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr. Res. 61 (2003) 303-314
17. Jones B., Basson B.R., Walker D.J., Crawford A.M., and Kinon B.J. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J. Clin. Psychiatry 62 Suppl 2 (2001) 41-44
18. Bai Y.M., Lin C.C., Chen J.Y., Lin C.Y., Su T.P., and Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am. J. Psychiatry 163 (2006) 1276-1279
19. Kinon B.J., Basson B.R., Gilmore J.A., and Tollefson G.D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry 62 (2001) 92-100